AbbVie snaps up CAR-T company in a deal worth $2.1 billion - STAT
STATarrow_outwardAbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion - WSJ
WSJarrow_outwardAbbVie to buy Capstan Therapeutics for up to $2.1 billion - TradingView
TradingViewarrow_outwardAbbVie to buy Capstan Therapeutics for up to $2.1 billion
Reutersarrow_outwardAbbVie bags Capstan’s in vivo CAR-T work with $2.1B buyout deal
Endpoints Newsarrow_outwardAbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
Longview News-Journalarrow_outwardAbbVie to buy Capstan Therapeutics for up to $2.1 billion - MarketScreener
MarketScreenerarrow_outwardAbbVie to acquire Capstan Therapeutics for up to $2.1 billion - Investing.com
Investing.comarrow_outwardAbbVie (ABBV) to Acquire Capstan Therapeutics for $2.1 Billion - StreetInsider
StreetInsiderarrow_outwardCapstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease - Business Wire
Business Wirearrow_outwardSoon, cancer-fighting cells could be engineered inside our bodies - NewsBytes
NewsBytesarrow_outwardCancer-fighting immune cells could soon be engineered inside our bodies - Nature
Naturearrow_outwardRecent myositis trials produce both ‘successes and failures’ - Healio
Healioarrow_outwardSome of the Key Players in In vivo CAR T-cell Market: - InsightAce Analytic
InsightAce Analyticarrow_outwardAllogeneic cell therapies “poised for prime time” says expert - Pharmaceutical Technology
Pharmaceutical Technologyarrow_outwardCapstan Therapeutics to Participate in Upcoming Investor Conferences - BioSpace
BioSpacearrow_outwardSix immunology biotech companies revolutionizing immune treatments in 2024 - Labiotech.eu
Labiotech.euarrow_outwardThe History and Future of CAR T with Bruce Levine - Andreessen Horowitz
Andreessen Horowitzarrow_outwardIs a better CAR-T cell therapy option on the horizon? - PharmaVoice
PharmaVoicearrow_outwardCapstan Therapeutics - The Pharma Letter
The Pharma Letterarrow_outwardThe effort to make a breakthrough cancer therapy cheaper - MIT Technology Review
MIT Technology Reviewarrow_outwardTop 20 biotech startups raise $2.9B in Q1 2024 funding surge - drugdiscoverytrends.com
Drugdiscoverytrends.comarrow_outwardForbion participates in US financing rounds - European Biotechnology Magazine
European Biotechnology Magazinearrow_outwardIL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation - PNAS
PNASarrow_outwardCapstan heats up ‘in vivo’ cell therapy chase with $175M fundraise - BioPharma Dive
BioPharma Divearrow_outwardJohnson & Johnson, Pfizer, Eli Lilly and other big pharmas are backing this San Diego biotech with $175M - San Diego Union-Tribune
San Diego Union-Tribunearrow_outwardCapstan reels in $175M for in vivo CAR-T reprogramming play - FirstWord Pharma
FirstWord Pharmaarrow_outwardAs Cell Therapy Gains Ground, Efforts Emerge to Improve CAR T-Manufacturing - MedCity News
MedCity Newsarrow_outwardCapstan Therapeutics Appoints Athena Countouriotis, M.D., as Board Chair - citybiz
Citybizarrow_outwardStarry syndicate powers $165M bet on in vivo CAR-T therapies, enabling Penn spinout Capstan to set sail - Fierce Biotech
Fierce Biotecharrow_outwardCapstan Therapeutics launches with $165 million for cell engineering - Chemical & Engineering News
Chemical & Engineering Newsarrow_outwardAnother Philadelphia story: Capstan premieres with $165M investment - BioWorld MedTech
BioWorld MedTecharrow_outwardPenn spinout Capstan Therapeutics launches with $165M and an all-star lineup of founders - The Business Journals
The Business Journalsarrow_outwardMichael Baran, MBA, PHD - Pfizer
Pfizerarrow_outward
Capstan Therapeutics close
- 2025-06-30 20:50 event
- 34 sourceslanguage
- 200+ ads_click
- 3 weeks ago schedule